PRQR:NASDAQProQR Therapeutics N.V. Analysis

ProQR is trading at $1.55, well below its 20‑day SMA of 1.77 and 50‑day SMA of 1.67, while the 200‑day SMA remains at 2.04, highlighting a clear price weakness. The RSI sits around 41 and the MACD histogram is bearish, pointing to neutral‑to‑down momentum, and a decreasing volume trend combined with a staggering 30‑day volatility of ~92% and a beta near 1.68 underscores the stock’s extreme price swings. Fundamentally, the company posted modest 6% revenue growth to $16.3 M, yet operating and profit margins are deeply negative and cash flow is –$52 M, although a solid cash balance of $92 M offsets $16 M of debt. The PE ratio is negative and forward PE –3.3, reflecting a lack of earnings, and the dividend is nonexistent.
Recent material news adds a catalyst: a partnership with Ginkgo Bioworks and the formation of an AI advisory board aim to accelerate the Axiomer platform, with the first AI‑discovered candidate expected to enter the clinic in 2026. AX‑0810 target‑engagement data in healthy volunteers are on track, and biliary atresia has been selected for Phase 2, potentially extending the company’s runway. While these developments could unlock significant upside if milestones are achieved, the current technical setup and cash‑burn profile keep short‑term risk elevated, demanding investors balance high upside potential against near‑term volatility and earnings uncertainty.